INTRODUCTION
============

Upper urinary tract urothelial carcinoma (UTUC), which originates from the urothelial lining, can be located in pyelocaliceal cavities and ureter. The incidence of UTUC is much less than that of bladder cancer, accounting for 10% of renal tumors and 5% of all urothelial malignancies.[@B1][@B2][@B3] The standard operation method for UTUC is radical nephroureterectomy (RNU) with removing bladder cuff, regardless of high-risk noninvasive and invasive UTUC.[@B4][@B5] However, invasive UTUC accounts for approximately 60% of total cases, which is much higher than the invasive percentage of bladder cancer.[@B5] The outcome is still commonly poor with a high recurrence rate ranging from 30% to 75% in UTUC.[@B2][@B6] Several studies have shown that patient\'s age, history of bladder cancer, tumor stage, tumor grade, lymph node metastasis, necrosis, multifocality, and hydronephrosis are independent prognostic factors connected to disease recurrence or survival.[@B1][@B6][@B7][@B8]

Lymphovascular invasion (LVI) is a significant and crucial step in the systemic dissemination of cancer cells.[@B9] LVI has also been discovered as a prognostic factor in UTUC.[@B10][@B11][@B12][@B13][@B14] However, the influence of LVI on prognosis was meaningless in some studies,[@B15][@B16][@B17] which remains a controversial problem. In pathological reports, LVI was routinely assessed but not documented in all cases, and not described as a prognostic factor.[@B10] Since LVI predicted that lymph node metastasis was a prognostic factor in UTUC patients,[@B18][@B19] focusing on node-negative patients might have great significance in discovering high-risk factors in patients with node-negative UTUC. In the present study, we aimed to further validate the prognostic value of LVI in patients with UTUC, especially in those with node-negative UTUC undergoing RNU. Improved understanding of prognostic influence of LVI can help us make better prognostic evaluations and more appropriate regimen of adjuvant chemotherapy.

MATERIALS AND METHODS
=====================

Ethical approval
----------------

The study protocol was approved by ethics committee at our institution. All patients involved in this retrospective study have given written informed consent. We made sure that all samples were anonymous.

Patient selection and follow-up
-------------------------------

From 2005 to 2013, 180 patients, who were diagnosed with UTUC and treated with RNU in our institution, were analyzed retrospectively. When lymph node enlargement was doubtable on preoperative CT or enlarged during intraoperative examinations, regional lymphadenectomy was routinely performed without extending lymphadenectomy. Patients with incomplete clinical data, non-UTUC, or distant metastasis were excluded. Finally, 180 patients were enrolled in this study.

The study end was recurrence-free survival (RFS) and cancer-specific survival (CSS) after RNU. Disease RFS was defined as local recurrence and lymph node and/or distant metastasis, except the contralateral upper urinary tract or subsequent bladder recurrences. We defined CSS according to death certificates and results estimated by treating physicians. However, patients who died within 30 days of surgery or before discharge were not included as disease recurrence and cancer-specific death cases.

Pathologic evaluation
---------------------

All specimens were re-reviewed by two genitourinary pathologists according to standard pathologic procedures, to ensure the validity of pathologic data extraction. Tumor stage was assessed according to the 2018 American Joint Committee on Cancer (AJCC) TNM staging system. Tumor grade was evaluated according to the 2016 World Health Organization grading system.[@B20] The clinicopathological data of patients included age, history of bladder cancer, tumor stage, tumor grade, lymph node involvement, necrosis, multifocality, and hydronephrosis.

Hematoxylin and eosin (H&E) staining is regularly performed in our institute to identify LVI, which is defined pathologically as the presence of tumor cells within a definite endothelium-lined space without underlying muscular walls both in the intratumoral and peritumoral area, or spaces in vascular lined by plump cells at the peritumoral area ([Fig. 1A](#F1){ref-type="fig"}).[@B21] Erythrocytes or fibrin clots in blood vessels, and the lack of smooth muscle or elastic fibers in lymphatic vessels can help pathologists to identify vessels and LVI. Immunohistochemical (IHC) staining is not routinely used to assess LVI, unless two pathologists cannot reach an agreement on the confirmation of LVI in one slide ([Fig. 1B](#F1){ref-type="fig"}). However, it is difficult to distinguish between vascular and lymphatic invasion due to the difficulty and the lack of reproducibility when using routine light microscopic examinations. Nodal status was assessed by pathologists when lymph nodes were retrieved during operation.

Statistical analysis
--------------------

Statistical analyses were performed by SPSS v.16.0 (SPSS Inc., Chicago, IL, USA). The correlation between LVI and other clinicopathological characteristics was tested by χ^2^ test or Fisher\'s exact test. Survival curve for the presence of LVI was estimated with Kaplan-Meier method, and differences were assessed by log-rank statistic. Univariate and multivariate regression analyses were performed with Cox proportional hazards regression model to explain the impact of LVI on RFS and CSS respectively, or in patients without lymph nodes involvement. The results showed that hazard ratios (HRs) served as relative risks with corresponding 95% confidence intervals (CIs). All reported *p* values were two-sided, and statistical significance was set at *p*≤0.05.

RESULTS
=======

Patient characteristics
-----------------------

Our study included 180 patients with UTUC, consisting of 109 males (60.6%) and 71 females (39.4%). Clinicopathological characteristics are listed in [Table 1](#T1){ref-type="table"}. The average age of these 180 patients was 67.2 years (ranging from 39 to 87 years), and the mean follow-up period was 45.4 months (ranging from 3 to 180 months).

Association of LVI with clinicopathological features
----------------------------------------------------

LVI, present in 28 patients (15.6%), was significantly associated with advanced pathological stage (*p*\<0.001), tumor necrosis (*p*=0.012), lymph nodes metastasis (*p*=0.017), and multifocality (*p*=0.012) ([Table 1](#T1){ref-type="table"}). Exclusion of lymph node-positive patients did not alter the significant correlation of LVI with advanced pathological stage (*p*=0.008), tumor necrosis (*p*=0.007), and multifocality (*p*=0.007) (data not shown).

Correlation of LVI with clinical prognosis in all patients
----------------------------------------------------------

LVI was closely associated with RFS and CSS ([Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). During follow-up, 39 patients (21.7%) experienced disease recurrence and 31 patients (17.2%) died of UTUC. The 5-year RFS rate was 84.8% in the absence of LVI and 35.0% in the presence of LVI (*p*\<0.001) ([Fig. 2A](#F2){ref-type="fig"}). The 5-year CSS rate was 87.5% in the absence of LVI and 25.2% in the presence of LVI (*p*\<0.001) ([Fig. 2B](#F2){ref-type="fig"}). Univariate analysis revealed that LVI were associated with RFS and CSS (double *p*\<0.001). After adjusting for the impact of factors including patient\'s age, tumor stage, tumor grade, lymph node metastasis, and multifocality, multivariate analysis suggested that LVI was an independent prognostic factor of RFS (HR=2.954; 95% CI=1.539--5.671; *p*=0.001) ([Table 2](#T2){ref-type="table"}) and CSS (HR=3.530; 95% CI=1.701--7.325; *p*=0.001) ([Table 3](#T3){ref-type="table"}).

Correlation of LVI with clinical prognosis in node-negative patients
--------------------------------------------------------------------

The number of patients with node-negative UTUC was 169. In patients without lymph node involvement, the 5 year RFS and CSS rates were 84.1% and 86.9%, respectively, in the absence of LVI, compared to 33.8% and 21.7%, respectively, in the presence of LVI (double *p*\<0.001) ([Fig. 3](#F3){ref-type="fig"}). LVI was an independent prognostic factor of RFS (HR=3.732; 95% CI 1.866--7.464; *p*\<0.001) ([Table 4](#T4){ref-type="table"}) and CSS (HR=3.825; 95% CI=1.777--8.234; *p*=0.001) ([Table 5](#T5){ref-type="table"}).

DISCUSSION
==========

LVI has been proven to be a significant prognostic factor in various malignancies such as liver, testis, and penile cancer.[@B12] Some studies have estimated that LVI was a poor prognostic predictor in patients with UTUC after RNU.[@B10][@B11][@B12][@B13] However, the influence of LVI in prognosis was meaningless in other studies,[@B15][@B16][@B17] which remains a controversial problem.

In consonance with previous studies, our results indicated that LVI was a poor independent predictor of RFS (*p*=0.001) and CSS (*p*=0.001) in UTUC patients.[@B10][@B11][@B12][@B13] Most node-positive patients with UTUC had early distant metastasis after RNU.[@B19] Since lymph node involvement was thought as an adverse factor in UTUC, focusing on node-negative patients might have a great significance in discovering the high-risk factors in them. However, only a few studies analyzed the association between LVI and the outcome of patients with node-negative UTUC. In node-negative patients, multivariate analysis suggested that LVI was associated with poor prognosis in RFS (*p*\<0.001) and CSS (*p*=0.001). Therefore, our study suggested that LVI was also a poor predictor of RFS and CSS in node-negative patients. On this basis, pathologic assessment of UTUC specimens should be routinely recorded for LVI, especially in node-negative ones. In addition, LVI was associated with established features of UTUC, such as advanced pathological tumor stage, presence of tumor necrosis, and multifocality, which are all independent poor prognostic factors.[@B6][@B7][@B8] Nowadays, tumor stage is the most important prognostic indicator of UTUC. We acquired the same results that advanced pathological tumor stage was an important prognostic factor in RFS (HR=13.688; 95% CI=5.55--33.755; *p*\<0.001) and CSS (HR=12.782; 95% CI=4.33--37.756; *p*\<0.001), respectively.

LVI has been involved in TNM classification of some tumors, such as lung cancer, colorectal cancer, gastric cancer, and testicular cancer,[@B22][@B23][@B24][@B25] which meant that LVI might have a similar significance in TNM classification. In non-small-cell lung cancer (NSCLC), stage IA with vascular invasion (VI) and stage IB had equivalent prognostic outcomes, suggesting that pT IA NSCLC with VI should be upstaged similar to pT IB NSCLC.[@B22] Ahmed Farag, et al.[@B23] found that adding LVI to TNM classification of colorectal cancer could help the physician provide more aggressive treatment strategies for patients with early TNM stage with LVI. In nonseminomatous germ cell tumor, stage I patients with LVI were advocated to accept adjuvant chemotherapy compared to patients without LVI advocated to accept surveillance.[@B25] According to our results, LVI should be evaluated as reference criteria for high risk stratification and included in TNM classification system for UTUC, especially for patients with node-negative UTUC. Further prospective studies should focus more on the influence of LVI on UTUC patients of different TNM stages.

LVI was defined as the presence of tumor cells within an endothelium-lined space of vascular or lymphatic vessels without underlying muscular walls both in the intratumoral and peritumoral area, or spaces in vascular lined by plump cells at the peritumoral area.[@B21] It is an important step in the mechanisms of tumor growth, lymph node involvement, and distant metastasis. There was no prognostic value of LVI in node-positive patients (data not shown) compared to node-negative ones. LVI and metastatic lymph nodes had a powerful association (*p*=0.017), which suggested that LVI might be an essential step for lymph node metastasis, and can prompt to seek for occult metastasis during the operation. Therefore, LVI can give a hint about whether or not regional lymph nodes should be removed. While H&E staining has lower diagnostic accuracy in detecting LVI compared with using IHC staining, increasing application of IHC staining could reap more reliable result.

On account of the currently insufficient data of UTUC, the effect of adjuvant chemotherapy in UTUC still remains controversial.[@B26][@B27] Some studies showed that adjuvant chemotherapy improved CSS in patients with node-positive UTUC or positive LVI.[@B28][@B29] Therefore, application of adjuvant chemotherapy should be personalized according to the situation of LVI or lymph node involvement. In node-negative patients with UTUC, the association of LVI with the effect of adjuvant chemotherapy has not been proven. Unfortunately, due to the limitation of sample size, we did not analyze the effect of adjuvant chemotherapy in patients with node-negative UTUC. While our results presented that LVI was a high-risk prognostic factor in node-negative patients with UTUC, it is probably an indicator guiding more accurate administration of adjuvant chemotherapy in node-negative patients.

There are several limitations in our study. First, this study had a single-center retrospective design, which carries an intrinsic bias. Further prospective study in a large-scale population should be performed to explore the prognostic implication of LVI in UTUC. Second, lymph node metastasis was proven as an outcome predictor in other results.[@B11][@B13] We did not verify its prognostic role in our study. This was due to the small size of our enrolled patients, especially the node-positive patients. However, the prognostic implication of LVI in node-negative patients was more importantly and powerfully investigated in our study. Third, the criterion of LVI might have a bias due to the relatively lower accuracy compared to IHC staining. However, the application of IHC staining was limited on the account of its price and other reasons worldwide.

In summary, LVI is an independent adverse prognostic factor in patients with node-negative UTUC after RNU, which is linked to shorter RFS and CSS. LVI can be estimated as a selection criterion for high risk stratification, and help physicians make decisions on accurate administration of adjuvant chemotherapy. LVI should be routinely estimated in histological specimens.
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![Lymphovascular invasion (arrow) in upper urinary tract urothelial carcinoma was shown in hematoxylin and eosin staining (A) and immunohistochemical staining (CD31) (B); ×400.](ymj-60-174-g001){#F1}

![Kaplan-Meier curves of disease RFS (A) and CSS (B) stratified by LVI in 180 patients with upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy. RFS, recurrence-free survival; CSS, cancer-specific survival; LVI, lymphovascular invasion.](ymj-60-174-g002){#F2}
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###### Association of Lymphovascular Invasion with Clinical and Pathologic Characteristics of Patients Treated with Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma

![](ymj-60-174-i001)

                              Cases (%)    Lymphovascular invasion               
  --------------------------- ------------ ------------------------- ----------- -------
  Gender                                                                         0.214
   Male                       109 (60.6)   95 (62.5)                 14 (50.0)   
   Female                     71 (39.4)    57 (37.5)                 14 (50.0)   
  Age (yr)                                                                       0.563
   \<70                       99 (55.0)    85 (55.9)                 14 (50.0)   
   ≥70                        81 (45.0)    67 (44.1)                 14 (50.0)   
  Smoking                                                                        0.076
   Yes                        52 (28.9)    40 (26.3)                 12 (42.9)   
   No                         128 (71.1)   112 (87.5)                16 (57.1)   
  History of bladder cancer                                                      0.994
   No                         164 (91.1)   139 (91.4)                25 (89.3)   
   Yes                        16 (8.9)     13 (8.6)                  3 (10.7)    
  Pathologic tumor stage                                                         0.001
   Ta--T2                     115 (63.9)   105 (69.1)                10 (35.7)   
   T3--T4                     65 (36.1)    47 (30.9)                 18 (64.3)   
  Tumor grade                                                                    0.194
   G1--G2                     91 (50.6)    80 (52.6)                 11 (39.3)   
   G3                         89 (49.4)    72 (47.4)                 17 (60.7)   
  Tumor necrosis^\*^                                                             0.012
   Absent                     173 (96.1)   149 (98.0)                24 (85.7)   
   Present                    7 (3.9)      3 (2.0)                   4 (14.3)    
  Multifocality^\*^                                                              0.012
   Unifocal                   173 (96.1)   149 (98.0)                24 (85.7)   
   Multifocal                 7 (3.9)      3 (2.0)                   4 (14.3)    
  Lymph node metastasis                                                          0.017
   Absent                     169 (93.9)   146 (96.1)                23 (82.1)   
   Present                    11 (6.1)     6 (3.9)                   5 (17.9)    
  Hydronephrosis                                                                 0.737
   Absent                     72 (40.0)    60 (39.5)                 12 (42.9)   
   Present                    108 (60.0)   92 (60.5)                 16 (57.1)   

^\*^Fisher\'s exact test.

###### Univariate and Multivariate Cox Regression Analyses of All Patients for Disease Recurrence-Free Survival
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  Variable                    Univariate analysis      Multivariate analysis                           
  --------------------------- ------------------------ ----------------------- ----------------------- ---------
  Gender                                               0.937                                           
  Age (yr)                    2.310 (1.217--4.384)     0.010                                           
  Smoking                     2.242 (1.186--4.239)     0.013                                           
  History of bladder cancer                            0.277                                           
  Pathologic tumor stage      17.972 (7.389--43.496)   \<0.001                 13.688 (5.55--33.755)   \<0.001
  Grade                       2.637 (1.334--5.211)     0.005                                           
  Lymphovascular invasion     6.007 (3.170--11.382)    \<0.001                 2.954 (1.539--5.671)    0.001
  Tumor necrosis                                       0.103                                           
  Multifocality               3.284 (1.008--10.696)    0.048                                           
  Lymph node metastasis                                0.749                                           
  Hydronephrosis                                       0.919                                           

CI, confidence interval; HR, hazard ratio.

###### Univariate and Multivariate Cox Regression Analyses of all Patients for Cancer-Specific Survival
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  Variable                    Univariate analysis      Multivariate analysis                           
  --------------------------- ------------------------ ----------------------- ----------------------- ---------
  Gender                                               0.912                                           
  Age (yr)                    3.498 (1.643--7.448)     0.001                                           
  Smoking                     2.683 (1.323--5.441)     0.006                                           
  History of bladder cancer                            0.650                                           
  Pathologic tumor stage      18.231 (6.357--52.284)   \<0.001                 12.782 (4.33--37.756)   \<0.001
  Grade                       2.206 (1.038--4.686)     0.040                                           
  Lymphovascular invasion     7.595 (3.722--15.495)    \<0.001                 3.530 (1.701--7.325)    0.001
  Tumor necrosis                                       0.053                                           
  Multifocality               4.013 (1.212--13.288)    0.023                                           
  Lymph node metastasis                                0.491                                           
  Hydronephrosis                                       0.880                                           

CI, confidence interval; HR, hazard ratio.

###### Univariate and Multivariate Cox Regression Analyses of Node-Negative Patients for Disease Recurrence-Free Survival
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  Variable                    Univariate analysis      Multivariate analysis                           
  --------------------------- ------------------------ ----------------------- ----------------------- ---------
  Gender                                               0.588                                           
  Age (yr)                    2.078 (1.072--4.026)     0.030                                           
  Smoking                                              0.099                                           
  History of bladder cancer                            0.258                                           
  Pathologic tumor stage      17.914 (7.199--44.581)   \<0.001                 15.269 (6.01--38.785)   \<0.001
  Grade                       2.624 (1.289--5.340)     0.008                                           
  Lymphovascular invasion     6.097 (3.082--12.063)    \<0.001                 3.732 (1.866--7.464)    \<0.001
  Tumor necrosis                                       0.099                                           
  Multifocality               3.400 (1.039--11.125)    0.043                                           
  Hydronephrosis                                       0.860                                           

CI, confidence interval; HR, hazard ratio.

###### Univariate and Multivariate Cox Regression Analyses of Node-Negative Patients for Cancer-Specific Survival
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  Variable                    Univariate analysis      Multivariate analysis                           
  --------------------------- ------------------------ ----------------------- ----------------------- ---------
  Gender                                               0.701                                           
  Age (yr)                    3.114 (1.431--6.775)     0.004                                           
  Smoking                                              0.055                                           
  History of bladder cancer                            0.602                                           
  Pathologic tumor stage      16.768 (5.786--48.593)   \<0.001                 12.414 (4.19--36.784)   \<0.001
  Grade                                                0.051                                           
  Lymphovascular invasion     7.445 (3.500--15.835)    \<0.001                 3.825 (1.777--8.234)    0.001
  Tumor necrosis                                       0.058                                           
  Multifocality               4.264 (1.277--14.241)    0.018                                           
  Hydronephrosis                                       0.648                                           

CI, confidence interval; HR, hazard ratio.
